top
    Home
    Welcome Note
    Registration
    Accommodation
    Contact Us
     Home
     Welcome Note
     Congress Chairpersons
     Scientific Committee
     Faculty
     Scientific Program
     Timetable
     CME
     Young Investigators Posters
         Poster List
         Poster Award Ceremony
         Poster Presentation Guidelines
     Sponsorship & Exhibition
     Sponsors
     Past Sponsors
     Endorsements
     Registration
         Invitation Letter
     Accommodation
         Leonardo Royal Hotel Berlin
     General Information
         At the C-Hep Congress
         C-Hep 2012 Photos
         Before you travel...
         Tips and Hints
         Transportation
         Italian Agent
         Chinese Agent
     Partners
     About Berlin
     C-Hep 2011
  

 
  Scientific Program Print
 
Thursday, October 18, 2012

14:00-16:00
PLENARY SESSION 1
HALL A
HEPATITIS C – ADDRESSING THE CHALLENGE
Moderators: Jürgen Rockstroh, Germany & Jonathan Schapiro, Israel
14:00-14:05
Chairpersons Congress Welcome Address
14:05-14:30
HCV in 2020: Any cases left? Rafael Esteban, Spain
14:30-14:35
Discussion
14:35-15:00
HCV vaccine: Where do we stand? Ulrich Spengler, Germany
15:00-15:05
Discussion
Interferon-free HCV therapy: Are we getting there?
15:05-15:25
No: Graham Foster, UK
15:25-15:45
Yes: Heiner Wedemeyer, Germany
15:45-16:00
Discussion
16:00-17:30
Pipeline Showcase: New Drugs on the Horizon HALL A
Chairperson: Jonathan M. Schapiro , Israel
16:00-16:05 Introduction
16:05-16:20 Strategies towards cure of HCV infection: a personalized approach
Heiner Wedemeyer,
Germany
Presentation Supported by BMS
16:20-16:35 Combination DAA Therapy for Hepatitis C
Douglas Mayers,
USA
Presentation Supported by Idenix
16:35-16:50
Host targeting therapies for the treatment of Hepatitis C
Claudio Avila,
Switzerland
Presentation Supported by Novartis
16:50-17:05 The ANNAPURNA study: Evaluating the Combination of Setrobuvir, Danoprevir/r and Ribavirin With or Without Mericitabine in Patients With Chronic Hepatitis C
Eckart Schott,
Germany
Presentation Supported by Roche
17:05-17:20 Silibinin dihydrogensuccinate for the prevention of hepatitis C recurrence after liver transplantation and treatment of non-responders to anti-HCV therapy,
Lucio Rovati,
Italy
Presentation Supported by Rottapharm | Madaus
17:20-17:30 Panel Discussion
17:30-18:00
Coffee Break and Poster Exhibition
18:00-19:15
Janssen Satellite Symposium
DAAs: Raising Standards in Patient Care
HALL A
18:00-18:05
Welcome and introduction: Thomas Berg , Germany
18:05-18:25
Practical recommendations in the era of DAAs: Vlad Ratziu , France
18:25-18:45
Managing DAA treatment in HIV-HCV co-infected patients: Massimo Puoti, Italy
18:45-19:05
Understanding our patients: challenging clinical cases: Marina Berenguer, Spain
19:05-19:15
Summary and key learnings: Thomas Berg , Germany
19:15-20:30
Welcome Reception, Sponsored by Abbott


Friday, October 19, 2012

09:00-11:00
PLENARY SESSION 2
HALL A
HCV DIRECT ACTING ANTIVIRALS: HOW HAVE THE TREATMENT PARADIGMS CHANGED
Moderators: Stefan Zeuzem, Germany & Eckart Schott, Germany
09:00-09:05
Overview of HCV sessions by HCV Program Director
Stefan Zeuzem , Germany
Direct Antivirals: How have the treatment paradigms changed?
09:05-09:10
Moderators Introduction
HCV Direct Acting Antivirals:
09:10-09:30
In treatment naïve: Stanislas Pol, France
09:30-09:50
In treatment experienced: Thomas Berg, Germany
09:50-10:10
Toxicity management: Christoph Hezode, Paris
10:10-10:40
Drug-drug interactions: David Back, UK
10:40-11:00
Panel discussion
11:00-11:30
Coffee Break

11:30-12:15
SESSION 3: DO WE NEED TO KNOW GENETIC FACTORS SUCH AS IL28B FOR TREATMENT DECISION MAKING? (parallel session)
HALL A
Moderator: Christoph Sarrazin, Germany
11:30-11:45
Yes: Vincent Soriano, Spain
11:45-12:00
No: Mathew Albert, France
12:00-12:15
Discussion

11:30-12:15
SESSION 4: HCV THERAPY IS FOR SPECIALISTS ONLY? (parallel session)
HALL B
Moderator: Geoffrey Dusheiko, Germany
11:30-11:45
Yes: Marion Peters, USA
11:45-12:00
No: Michael Biermer, Germany
12:00-12:15
Discussion
12:15-13:00
Lunch Break
13:00-14:15
Merck Sharp & Dohme Satellite Symposium
Successful HCV Treatment in the Real World: Lessons From Clinical Practice
Chairperson: Jürgen Rockstroh, Germany
HALL A
13:00-13:05
Welcome and Opening Remarks: Jürgen Rockstroh, Germany
13:05-13:20
Emerging Evidence Guiding Clinical Practice: Christoph Sarrazin, Germany
13:20-13:40
Optimizing Outcomes with Protease Inhibitors: Adverse Events Management and Prevention of Resistance: Jean Michel Pawlotsky, France
13:40-14:00
Protease Inhibitors in Practice:Case Studies: Geoffrey Dusheiko, UK
14:00-14:10
Panel Discussion
14:10-14:15
Closing Remarks: Jürgen Rockstroh, Germany

14:15-15:45
PLENARY SESSION 5
HALL A
HEPATITIS: STATE OF THE ART CLINICAL CARE
Moderators: Marion Peters, USA & Massimo Puoti, Italy
14:15-14:35
Fatty liver disease: what do we know? Claus Niederau, Germany 
14:35-14:55
Vitamin D and liver disease: Which role does it play? Christian M. Lange, Germany
14:55-15:15
End-stage liver disease: What is new? Marion Peters, USA
15:15-15:35
Treatment of HCC: state of the Art: Massimo Puoti, Italy
15:35-15:45
Panel Discussion
15:45-16:15
Coffee Break and Poster Prize Ceremony

16:15-17:00
SESSION 6 (parallel session)
HALL A
SHOULD PATIENTS WAIT FOR DAA COMBINATION THERAPY
Moderator: Vincent Soriano, Spain
16:15-16:30
Yes: Patrick Ingiliz , Germany
16:30-16:45
No: Geoffrey Dusheiko, UK
16:45-17:00
Discussion

16:00-17:00
SESSION 7 (parallel session)
HALL B
RESISTANCE TO HCV PROTEASE INHIBITORS: GAME OVER?
Moderator: Jonathan M. Schapiro , Israel
16:15-16:30
Yes: Jean Michel Pawlotsky , France
16:30-16:45
Yes: Christoph Sarrazin , Germany
16:45-17:00
Discussion

17:00-17:30
SESSION 8 (parallel session)
INTERACTIVE CASE SESSION: HOW TO TREAT HCV RELAPSE AFTER LIVER TRANSPLANT
HALL A
Case discussion: How to treat HCV relapse after OLTX
 
Raffaele Bruno , Italy

17:00-17:30
SESSION 9 (parallel session)
INTERACTIVE CASE SESSION: HOW TO TREAT HCV IN HIV COINFECTION
Supported by an unrestricted grant from Boehringer Ingelheim
HALL B
Case discussion: How to treat HCV in HIV coinfection
 
Stefan Mauss , Germany


Saturday, October 20, 2012

08:30-10:30
PLENARY SESSION 10: HBV THERAPY IN 2012
HALL A
Moderators: Fabien Zoulim, France & Jörg Petersen, Germany
08:30-08:35
Overview of HBV sessions by HBV Program Director: Fabien Zoulim, France
08:35-09:00
Hepatitis B Therapy: State of the Art and open challenges: Jörg Petersen, Germany
Is there a need for combination therapy?
09:00-09:15
Yes: Florian van Boemmel, Germany
09:15-09:30
No: Maria Buti, Spain
09:30-09:50
HBV preventive and therapeutic vaccines: What is new? Marie-Louise Michel, France
09:50-10:10 Hepatitis Delta: What is new? Heiner Wedemeyer, Germany
10:10-10:30
Panel Discussion
10:30-11:00
Coffee Break

11:00-11:45
PLENARY SESSION 11:
INTERACTIVE CASE SESSION AND DISCUSSION: THE CHALLENGING HEPATITIS B CASE
Supported by an unrestricted grant from Gilead Sciences Europe Ltd.
HALL A
Moderator: Fabien Zoulim , France
Mark Nelson, UK
Karine Lacombe, France

11:45-12:45
PLENARY SESSION 12
HALL A
HCV-Looking to the Future
Moderator: Mark Thursz, UK & Jürgen Rockstroh, Germany
11:45-12:05
Strategies to prevent HCC: What can we do? Mark Thursz, UK
12:05-12:20
Can we afford HCV DAAs for all? Maud Lemoine, France
12:20-12:45
What are the remaining challenges in hepatitis research? Michael Manns, Germany
 12:45-13:00 Farewell Toast

 

Home    Contact Us   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 04/02/2014 Created by     WebStudio.co.il